This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AstraZeneca Stock Rises 15% YTD: Should You Buy, Sell or Hold?
by Kinjel Shah
AstraZeneca stock is up 15% so far in 2025 as blockbuster drugs and a robust oncology portfolio fuel growth despite looming headwinds.
Johnson & Johnson (JNJ) Could Be a Great Choice
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
Should You Invest in Johnson & Johnson (JNJ) Based on Bullish Wall Street Views?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Johnson & Johnson (JNJ) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Robotics and MedSurg Drive Stryker Growth Amid Margin Pressures
by Zacks Equity Research
SYK posts 11% sales growth and EPS beat for Q2, driven by Mako robotics and MedSurg strength, but faces cost and margin headwinds.
J&J Adds $63B in Market Cap in 3 Months: Time to Buy the Stock?
by Kinjel Shah
J&J shares gain 17.7% in three months, adding $63B to its market cap. Technical and pipeline momentum fuel investor interest.
Take the Zacks Approach to Beat the Market: LendingTree, AutoZone, J&J in Focus
by Abhinab Dasgupta
Zacks highlights winners like LendingTree, AutoZone, and Johnson & Johnson as its proven stock-picking strategies continue to shine.
Boost Your Portfolio With These Top-Ranked ETFs
by Yashwardhan Jain
With the Fed's first 2025 rate cut and upgraded growth outlook, ETFs in tech, financials, industrials and health care could benefit from momentum.
Can MRK's New Drugs Drive Long-Term Growth Amid Looming Keytruda LOE?
by Zacks Equity Research
Merck eyes new launches like Capvaxive and Winrevair, among others, to drive long-term growth as Keytruda nears loss of exclusivity.
Top Wide-Moat Stocks Worth a Look for Sustainable Growth
by Anindya Barman
MSFT, JNJ, NKE and SPGI use strong moats to fend off rivals and deliver consistent returns amid market shifts.
Johnson & Johnson (JNJ) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
Johnson & Johnson (JNJ) reached $174.16 at the closing of the latest trading day, reflecting a -1.72% change compared to its last close.
J&J Expects Innovative Medicines Growth Despite Stelara LOE: Here's Why
by Kinjel Shah
J&J sees Innovative Medicines growth in 2025, fueled by oncology and immunology drugs, despite steep Stelara sales erosion.
GSK to Invest $30B in U.S. R&D and Manufacturing Over 5 Years
by Zacks Equity Research
GSK commits $30B to U.S. R&D and manufacturing, with advanced AI-driven biopharma facilities set to expand jobs and innovation.
LLY's $5B Virginia Plant Plan: Will U.S. Manufacturing Shift Pay Off?
by Kinjel Shah
Eli Lilly will invest $5B in a new Virginia plant to make cancer drugs, creating 650 jobs amid Trump's tariff push.
ISRG Stock Down More than 13% in 3 Months: How to Play the Stock?
by Indrajit Bandyopadhyay
Intuitive Surgical shares are down 13% in three months as margin pressures weigh on the stock, but strong procedure growth keeps its long-term story intact.
JNJ Seeks EU Approval for Oral Psoriasis Drug Icotrokinra
by Zacks Equity Research
J&J seeks EMA's nod to icotrokinra for treating plaque psoriasis in adults and pediatric patients aged 12 years and older.
AbbVie Settles Rinvoq Patent Dispute: What It Means for the Stock
by Sundeep Ganoria
ABBV secures Rinvoq's market lead until 2037, boosting shares as strong sales and new indications fuel long-term growth prospects.
Is BDTX's Cash balance Enough to Successfully Develop Its NSCLC Drug?
by Ekta Bagri
Black Diamond sharpens focus on silevertinib after outlicensing BDTX-4933, cutting costs, and securing cash runway into late 2027.
Johnson & Johnson (JNJ) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $178.41, denoting a +1.49% move from the preceding trading day.
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novartis, Pfizer and Bayer
by Zacks Equity Research
Big Pharma faces tariff risks, patent cliffs, and regulatory pressure, but innovation and strong pipelines keep Eli Lilly, J&J, Novartis, Pfizer, and Bayer in focus.
5 Large Drug Stocks to Watch Despite Industry & Macro Headwinds
by Kinjel Shah
In the Large-Cap Pharmaceuticals industry, Lilly, J&J, Novartis, Pfizer and Bayer are worth retaining amid macro pressure and rising innovation.
J&J Gains FDA Approval for Inlexzoh, Strengthens Pipeline Momentum
by Kinjel Shah
J&J secures FDA approval for Inlexzoh, which boosts its Innovative Medicine pipeline and reinforces long-term growth momentum.
The Zacks Analyst Blog Highlights Johnson & Johnson, SAP, Coca-Cola, Hamilton Beach and SIFCO Industries
by Zacks Equity Research
Zacks highlights Johnson & Johnson, SAP, Coca-Cola, Hamilton Beach, and SIFCO Industries in its latest research roundup, showcasing both blue-chip resilience and micro-cap growth stories.
Ion Platform Poised for Cost Optimization: A Margin Lever for ISRG?
by Indrajit Bandyopadhyay
Intuitive Surgical's Ion platform is driving rapid growth, but cost optimization could be the key to turning it from a margin drag to a margin lever.